CSTL Castle Biosciences

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the Houston Chronicle. This is the fourth consecutive year the Company has been ranked among the Houston metro area’s top workplaces. Castle also earned three Culture Excellence awards in the areas of Employee Appreciation, Employee Well-Being and Professional Development.

“Achieving a Houston Top Workplace honor for the fourth straight year is truly remarkable,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “From the very beginning, we have prioritized a people-first culture, as our team members are the foundation of our success. This honor reflects their hard work and unwavering commitment to our mission of advancing patient care, which drives us forward each day.”

The program surveys and celebrates people-first organizations nationally and across 60 regional markets. Top Workplace designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey uniquely measures the employee experience and its component themes, including employees feeling “respected & supported,” “enabled to grow” and “empowered to execute,” among others. Additionally, it measures 15 culture drivers that it believes to be indicative of successful organizations, such as alignment, execution and connection.

The addition of these recent accolades brings the Company’s total 2024 Top Workplaces awards to 12, all representing multi-year wins, which include two regional awards for Houston and Arizona and ten national awards: Top Workplaces USA (ranking 28th among 370 participating companies with 500-999 employees), Top Workplaces Industry – Healthcare (ranking fourth out of 95 firms with 500 or more employees) and Top Workplaces Culture Excellence in Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, Purpose & Values, Employee Appreciation, Employee Well-Being and Professional Development.

The complete list of 2024 Houston Chronicle Top Workplaces can be viewed . Additional information regarding the Cultural Excellence Awards is available on the .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit and connect with us on , , and .

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to work together.TM

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or .

EN
19/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ ...

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (N...

 PRESS RELEASE

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financ...

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and ...

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide pati...

 PRESS RELEASE

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 I...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch